Example: stock market
Investor Update
Furthermore, the FDA granted two additional Breakthrough Therapy Designations (BTD): for Venclexta/Venclyxto combination therapy for the treatment of adult patients with myelodysplastic syndromes, a rare form of blood cancer. This marks the sixth BTD for Venclexta/Venclyxto.
Download Investor Update
Information
Domain:
Source:
Link to this page: